R&D shakeup: Merck taps former Amgen exec Perlmutter to replace Kim
This article was originally published in Scrip
Executive Summary
There may be an increased level of anxiety among research staff at Merck & Co. over the next few months as former Amgen executive Roger Perlmutter comes on board to replace Peter Kim as head of R&D. Perlmutter will have “broad discretion” to kill or move existing drug programs forward, according to Merck spokesperson Steven Cragle.
You may also be interested in...
Merck’s Perlmutter Is Retiring, Handing Over Keytruda To Li
Merck Research Laboratories president Roger Perlmutter returned to the company when its R&D was at a crossroads. Now he is retiring and handing the company’s post-Keytruda growth over to SVP Dean Li.
Baxter's Advate helps prevent bleeding in one-year study of hemophiliacs
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Bresch is looking to do a sizable deal
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.